Trial Information

Summary: Adult migraine butalbital users

Approximately 28 million Americans suffer from severe, throbbing migraine headaches. For some individuals these symptoms occur only once or twice a year, yet for others headaches attack multiple times a month. These frequent and severe headaches disrupt an individual’s life, both at home and work.

Currently, approximately 17%#37;of these migraine sufferers are treating their headaches with BUTALBITAL containing medications such as Fioricet®. These medications produce a sedative effect that allows many individuals to cope with their migraine symptoms. There has been no clinical research to show that these potentially-addictive treatments are effective in treating migraines. Some research even states that such medications may increase the frequency of migraine headaches if used too often.

It is for this reason that medical researchers are working to develop new medications that are both safe and effective for migraine sufferers.

Patient Inclusion Criteria:

• Must be 18 to 65 years of age.
• Currently suffering from migraines.
• Currently treating their migraines with BUTALBITAL-CONTAINING MEDICATIONS such as Fioricet®.

Patient Exclusion Criteria:

• Patients not currently treating their migraines with BUTALBITAL-CONTAINING MEDICATIONS such as Fioricet® will not be considered for the study.

Other specific exclusion criteria will be evaluated during the initial patient phone screening.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.